US-Funded Study on Hepatitis B Vaccines in Guinea-Bissau Canceled Due to Ethical Concerns
A highly contentious US-funded study on administering hepatitis B vaccines to newborns in Guinea-Bissau has been abruptly halted due to mounting ethical concerns. The $1.6 million research project, backed by Robert F Kennedy Jr., a long-time vaccine skeptic and former Secretary of the US Department of Health and Human Services (HHS), was widely criticized for its potential to deprive thousands of children of vital protection against the disease.
According to senior officials at the Africa Centers for Disease Control and Prevention (CDC), the study's design raised significant concerns about withholding vaccines proven to be effective in preventing hepatitis B. The CDC officials, led by Yap Boum, have welcomed the cancellation, citing the need for research to be conducted within established norms and guidelines.
Guinea-Bissau officials, however, claim that the trial will proceed once it has been redesigned to address these concerns. The country's current vaccination schedule will remain in place until the birth dose is implemented for all newborns in 2027.
The cancellation of this study comes as a relief for advocates who have long argued against unethical research practices in Africa. Paul Offit, an infectious diseases physician at the Children's Hospital of Philadelphia, described the development as "extremely heartening," highlighting the need to stand up against such studies and protect vulnerable populations.
Experts say that this cancellation represents a turning point for Guinea-Bissau and other countries where researchers are conducting work that critics deem unethical. Boghuma Titanji, an assistant professor of medicine at Emory University, emphasized the importance of research being conducted with ethics in mind and led by African scientists and powered by questions from Africans.
The study's design was met with skepticism due to concerns about potential nonspecific effects of adding other vaccines beyond the primary vaccine target. Researchers on the project argued that these interactions might be beneficial for overall health but lacked robust evidence to support their claims.
Notably, some Danish researchers associated with the study have been criticized for questioning the effectiveness of vaccines and not publishing results from a previous study on the diphtheria-tetanus-pertussis (DTP) vaccine. The cancellation has also drawn attention to potential conflicts of interest among researchers involved in the project, including ties to Trump administration health officials.
As the world continues to grapple with the complexities of vaccination research and ethics, this cancellation serves as a vital reminder of the need for rigorous oversight and accountability in scientific research, particularly when it comes to vulnerable populations.
A highly contentious US-funded study on administering hepatitis B vaccines to newborns in Guinea-Bissau has been abruptly halted due to mounting ethical concerns. The $1.6 million research project, backed by Robert F Kennedy Jr., a long-time vaccine skeptic and former Secretary of the US Department of Health and Human Services (HHS), was widely criticized for its potential to deprive thousands of children of vital protection against the disease.
According to senior officials at the Africa Centers for Disease Control and Prevention (CDC), the study's design raised significant concerns about withholding vaccines proven to be effective in preventing hepatitis B. The CDC officials, led by Yap Boum, have welcomed the cancellation, citing the need for research to be conducted within established norms and guidelines.
Guinea-Bissau officials, however, claim that the trial will proceed once it has been redesigned to address these concerns. The country's current vaccination schedule will remain in place until the birth dose is implemented for all newborns in 2027.
The cancellation of this study comes as a relief for advocates who have long argued against unethical research practices in Africa. Paul Offit, an infectious diseases physician at the Children's Hospital of Philadelphia, described the development as "extremely heartening," highlighting the need to stand up against such studies and protect vulnerable populations.
Experts say that this cancellation represents a turning point for Guinea-Bissau and other countries where researchers are conducting work that critics deem unethical. Boghuma Titanji, an assistant professor of medicine at Emory University, emphasized the importance of research being conducted with ethics in mind and led by African scientists and powered by questions from Africans.
The study's design was met with skepticism due to concerns about potential nonspecific effects of adding other vaccines beyond the primary vaccine target. Researchers on the project argued that these interactions might be beneficial for overall health but lacked robust evidence to support their claims.
Notably, some Danish researchers associated with the study have been criticized for questioning the effectiveness of vaccines and not publishing results from a previous study on the diphtheria-tetanus-pertussis (DTP) vaccine. The cancellation has also drawn attention to potential conflicts of interest among researchers involved in the project, including ties to Trump administration health officials.
As the world continues to grapple with the complexities of vaccination research and ethics, this cancellation serves as a vital reminder of the need for rigorous oversight and accountability in scientific research, particularly when it comes to vulnerable populations.